Results 111 to 120 of about 779,609 (165)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. [PDF]

open access: yesBMC Health Serv Res, 2022
Yoo HK   +7 more
europepmc   +1 more source

CT-P13: a safe and effective treatment for IBD [PDF]

open access: yesNature Reviews Gastroenterology & Hepatology, 2016
openaire   +1 more source

Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease [PDF]

open access: yesGastroenterology, 2017
Fiorino G   +11 more
openaire   +3 more sources

Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease. [PDF]

open access: yesDig Dis Sci
Fathallah N   +10 more
europepmc   +1 more source

Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease. [PDF]

open access: yesIntest Res
Nomaru R   +15 more
europepmc   +1 more source

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. [PDF]

open access: yesInflamm Bowel Dis
Schreiber S   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy